Evaluation of an attenuated, cold-recombinant influenza B virus vaccine.
Evaluation of an attenuated, cold-recombinant influenza B virus vaccine.
复制标题
减毒冷重组乙型流感病毒疫苗的评估。
DOI：
--
复制
发表时间：
1982
影响因子：
6.4
通讯作者：
H. F. Maassab
中科院分区：
文献类型：
--
作者：
A. Monto;F. D. Miller;H. F. Maassab
在一组学生中评估了一种减毒乙型流感病毒活疫苗。该病毒名为冷重组病毒（CR） 7，是由减毒的冷适应亲本B/Ann Arbor/1/66与野生毒株B/Hong Kong/8/73重组而成。在雪貂中，野生菌株在肺部产生组织病理学病变，而CR菌株和减毒亲本则没有。共有306人鼻内接种了CR病毒或安慰剂。接种后，只有一种症状在接种者中比在对照组中明显更常见。26%的疫苗接种者和10.5%的安慰剂接种者出现过短暂的喉咙痛症状。在接种疫苗三个月后爆发了乙型流感。比较两组患者血清学感染率，发现疫苗预防感染有显著效果（P < 0.01）。
A live, attenuated influenza B virus vaccine was evaluated in a group of students. The virus, cold-recombinant (CR) 7, was produced by recombining the attenuated cold-adapted parent, B/Ann Arbor/1/66, with a wild strain, B/Hong Kong/8/73. In ferrets, the wild strain produced histopathologic lesions in the lungs, whereas the CR strain and the attenuated parent did not. A total of 306 individuals was inoculated intranasally with either the CR virus or a placebo. After inoculation, only one symptom was significantly more common in the vaccinees than in the control subjects. That symptom, sore throat, occurred briefly in 26% of the vaccine recipients and in 10.5% of the placebo recipients. An outbreak of influenza B occurred three months after vaccination. When serologic infection rates in the two groups were compared, it was found that the vaccine had been significantly effective (P less than 0.01) in preventing infection.